In conclusion, the results of the present pilot study have shown an increase in CSF IL-6 levels and the IL-6/IL-17A ratio in SSVD patients compared to AD patients and controls, which deserve further evaluation in order to elucidate their potential role as surrogate biomarkers for the discrimination of SSVD from AD pathology. The gene discussed is IL17A; the disease is Alzheimer disease.